

C2R Conference

Imaging and Molecular Medicine in Urologic Oncology April 21-23 Toronto

2017

AGENDA

INTERACTIVE
AUDIENCE
Q & A
INCLUDED

C2R Organizing Committee
Laurence Klotz, MD, CM
Neil Fleshner, MD

C2R Events Patty Djan Inc.

Friday Evening April 21

- 6:00 – 6:45 Check In | Wellington Foyer
OPEN AUDIENCE ALL ATTENDEES WELCOME | Wellington Room
6:50 – 7:00 Friday Evening Welcome | Neil Fleshner, MD
7:00 – 8:35 **CASES CONFERENCE - MYSTERY DIAGNOSES** | Moderator: Joseph Chin, MD
7:10 – 7:15 Opening Remarks | Joseph Chin, MD
7:20 – 7:35 Clinical Case 1 | Gennady Bratslavsky, MD
7:40 – 8:00 (1) A Tale of Two Tumors | Tom Keane, MD
(2) To Be or Not To Be . . . A Thrombus | Tom Keane, MD
8:05 – 8:20 Bed to Bench to Bed | Joseph Chin, MD
8:25 – 8:40 Getting More Than You Bargained For | Peter Black, MD
8:45 – 11:00 **EVENING RECEPTION** | Rooftop Bar and Lounge (PERFORMANCE BY THE VOID)

Saturday Morning April 22

- 7:15 – 8:25 **PRIME INVESTIGATOR UPDATE** | Stewart Room | Bernie Eigl & Nawaid Usmani
7:45 – 8:25 **BREAKFAST REFRESHMENTS** | Wellington Foyer
Wellington Room **OPEN AUDIENCE** | ALL ATTENDEES WELCOME
8:30 – 8:35 **General Welcome & Framing the Theme: Imaging and Molecular Medicine in Urologic Oncology** | Laurence Klotz, MD
8:35 **SESSION ONE | INDUSTRY UPDATES & PIPELINE PRESENTATIONS** | Moderator: Neil Fleshner, MD
8:40 – 8:55 JANSSEN | ATLAS & TITAN UPDATES | Neil Fleshner, MD
8:55 – 9:10 PFIZER | How Far Can You Throw a Javelin? The Avelumab Clinical Development Program | Srikala Sridhar, MD
9:10 – 9:20 FERRING | FIT STUDY RESULTS | Laurence Klotz, MD
9:20 – 9:35 3DS INC. | 3D Signatures - Genomic Imaging for Precision Medicine | Jason Flowerday
9:35 – 9:50 BAYER | Science for a Better Life – The Future of GU Oncology at Bayer | Benjamin Ofori | CONFIDENTIAL - CLOSED
9:50 – 10:10 ASTELLAS | Pipeline: Urothelial Carcinomas | Bruce Brown | CONFIDENTIAL - CLOSED
10:15 – 10:35 **BREAK**
10:40 **SESSION TWO | IMAGING AND MOLECULAR MEDICINE IN PROSTATE CANCER** | Moderator: Andrew Loblaw, MD
10:45 – 11:00 3D Telomere Signatures in CTCs Indicate Radical Prostatectomy Outcome in Intermediate Risk Prostate Cancer Patients | Sabine Mai, PhD
11:00 – 11:15 Defining a Novel, Measurable Disease, Image-Based, Phenotype | Mark Emberton, MD
11:15 – 11:30 The Role of MRI in improving the Treatment of Prostate Cancer | Peter Pinto, MD
11:30 – 11:45 PSMA – Past and Present | Tom Keane, MD
11:45 – 12:00 Identifying the Optimal Screening Strategy for Prostate Cancer | David Penson, MD
12:00 – 12:10 Promise of Radioligand Therapy in Advanced Prostate Cancer | Neil Fleshner, MD
12:10 – 12:25 **DISCUSSION**
12:30 – 1:00 **LUNCH** - COLETTE RESTAURANT (Lobby Level)

Saturday Afternoon April 22

- 1:15 **SESSION THREE | MOLECULAR MEDICINE IN PROSTATE CANCER** | Moderator: Robert Bristow, MD
1:15 – 1:30 A Convergence of the Tumour Microenvironment and Genomics in Prostate Cancer | Robert Bristow, MD
1:30 – 1:50 The Three Genomes of Prostate Cancer: the Evolution of Tumour Aggressivity | Paul Boutros, PhD
1:50 – 2:05 Personalised Risk stratification for patients with prostate cancer: "PRONTO" | John Bartlett, PhD
2:05 – 2:25 Targeting Novel Sites on the Androgen Receptor to Inhibit Castration-Resistant Prostate Cancers | Paul Rennie, PhD
2:25 – 2:40 **DISCUSSION**
2:40 **SESSION FOUR | A PROVOCATIVE DISCUSSION** | Co-Moderators: Mark Emberton, MD & Laurence Klotz, MD
MAJOR OBSERVATIONS:
Objectives: Four key opinion leaders will identify the single most major observation in their field within the last 3 years. Each presenter will have 4 minutes to describe his or her observation, 4 minutes to put this into context and 4 minutes discussion.
PRESENTATIONS:
Observation #1 - MRI Targeted Prostate Biopsy: The New Gold Standard in 2017 | Peter Pinto, MD
Observation #2 - Epidemiology of Prostate Cancer Post USPSTF | David Penson, MD
Observation #3 - Cell Free Tumour DNA as a Predictive Biomarker and Diagnostic | Paul Rennie, PhD
Observation #4 - DNA Repair and Prostate Cancer Sensitivities: "Give me a Break!" | Robert Bristow, MD
DISCUSSION
3:40 – 3:55 **BREAK**
4:00 **SESSION FIVE | TOWN HALL DEBATE: HOW DO WE DEVELOP AND INTEGRATE EMERGING TECHNOLOGIES?**
Introduction by Laurence Klotz, MD | Co-Moderators: David Baskin, Mark Emberton, MD, and Laurence Klotz, MD
Panelists:
Randy AuCoin | Exact Imaging
John Bartlett | Ontario Institute of Cancer Research
Paul Boutros | University of Toronto
Shurjeel Choudhri | Bayer
Sherif Louis | 3D Signatures
Arun Menawat | Profound Medical
Peter Pinto | National Institutes of Health
4:45 – 5:00 **DISCUSSION**
5:00 **SESSION SIX | IMAGING AND MOLECULAR MEDICINE IN KIDNEY** | Moderator: Michael Jewett, MD
5:05 Understanding and Preserving the Molecular Profile of Kidney Cancer: Timeless Lessons | Gennady Bratslavsky, MD
5:20 Kidney Cancer Research Network of Canada (KCRNC) - Successes and Future Applications | Anil Kapoor, MD
5:35 Update on Systemic Therapy for RCC | Georg A. Bjarnason, MD
5:50 **DISCUSSION**
6:00 **SPECIAL GUEST LECTURE: INVESTING IN THE AGE OF UNCERTAINTY** | David Baskin, BA (Econ), LLB
6:20 **ADJOURN FOR DINNER**

Saturday Evening April 22

- 7:15 – 8:30 C2R Cocktails: LOBBY LOUNGE THOMPSON HOTEL
9:00 C2R Dinner STK Toronto, 153 Yorkville Ave. All Registered C2R Participants Welcome
*Pre-paid taxis will depart Hotel from 8:30 p.m.

Sunday Morning April 23

- 7:30 – 8:30 **BREAKFAST REFRESHMENTS** | WELLINGTON FOYER
Wellington Room **OPEN AUDIENCE** | ALL ATTENDEES WELCOME
8:45 **SESSION SEVEN | IMAGING AND MOLECULAR MEDICINE IN BLADDER CANCER** | Moderator: Neil Fleshner, MD
8:50 Molecular Markers of Response to Cisplatin-Based Chemotherapy in Bladder Cancer | Peter Black, MD
9:10 RNAseq and Molecular Grading of Non Muscle Invasive Bladder Cancer | Alexandre Zlotta, MD
9:30 **DISCUSSION**
9:40 **SESSION EIGHT | MRI Guided Therapy of Prostate Cancer** | Moderator: Tom Keane, MD
9:45 MRI Guided Focal Therapy | Joseph Chin, MD
10:00 MRI Guided RadioTherapy | Andrew Loblaw, MD
10:15 Molecular Imaging to Stage and Prognose Prostate Cancers Pre-Operatively | Frédéric Pouliot, MD
10:30 **BREAK**
10:45 **SESSION NINE | COLLABORATIVE RESEARCH PROJECTS** | Introduction by Laurence Klotz, MD
10:50 Report from Prostate Cancer Canada | Stuart Edmonds, PhD
11:00 THE PRECISION STUDY | Mark Emberton, MD
11:10 THE PRECISE STUDY & TRIPC | Laurence Klotz, MD and Paul Boutros, PhD
11:25 The PRIME STUDY | Prevention and Intervention for Metabolic Syndrome | Bernie Eigl & Nawaid Usmani
11:40 The Radical PC Trial | Exploring Cardiovascular Health in Prostate Cancer | Jehonathan Pinthus, MD
11:55 **DISCUSSION**
12:00 **ADJOURNMENT** | Laurence Klotz, MD

THOMPSON
TORONTO

550 Wellington St W
Toronto, ON M5V 2V4
(416) 640-7778
thompsonhotels.com

This conference has been made possible by funding from our sponsors:

Platinum



Gold



Silver



Bronze



With appreciation



Faculty & Participants:

Randy AuCoin
President and CEO
Exact Imaging

John Bartlett, PhD
Director, Transformative Pathology
Ontario Institute of Cancer Research

David Baskin, BA (Econ), LLB
President
Baskin Wealth Management

Georg A. Bjarnason, MD, FRCPC(C)
The Anna-Liisa Farquharson Chair in
Renal Cell Cancer Research
Associate Professor, Faculty of Medicine,
University of Toronto
Division of Medical Oncology, Sunnybrook
Odette Cancer Centre

Peter Black, MD, FACS, FRCSC
Khosrowshahi Family Chair in
Bladder Cancer Research
Associate Professor,
UBC Department of Urologic Sciences
Senior Research Scientist
Vancouver Prostate Centre

Paul C. Boutros, PhD, MBA
Principal Investigator,
Informatics & Biocomputing
Associate Professor,
Department of Medical Biophysics,
Department of Pharmacology and
Toxicology,
University of Toronto

Bruce Brown
Senior Medical Director, Oncology
US Medical Affairs
Astellas Pharma

Gennady Bratslavsky, MD
Professor and Chair
Department of Urology
750 East Adams Street
SUNY Upstate Medical University
Syracuse, New York

Robert Bristow, MD, PhD, FRCPC
Clinician-Scientist,
Ontario Cancer Institute/ Princess
Margaret Cancer Centre Professor,
Departments of Radiation Oncology
and Medical Biophysics
University of Toronto

J.L. Chin, O. Ont., MD, FRCSC
Professor of Urology & Oncology
Western University
London ON Canada

Shurjeel Choudhri, MD FRCPC
Senior Vice-President
and Head, Medical & Scientific Affairs
Bayer Inc.

Stuart Edmonds, PhD
Vice-President, Research,
Health Promotion & Survivorship
Prostate Cancer Canada

Bernhard J. Eigel, MD, FRCPC
Medical Oncologist, BC Cancer Agency
Provincial Director, Clinical Trials
Clinical Associate Professor,
University of British Columbia

Mark Emberton, MD, FRCS, Urol
Professor of Interventional Oncology, UCL
Honorary Consultant Urological Surgeon
UCH NHS Foundation Trust
London

Jason Flowerday, MBA
CEO, 3D Signatures Inc.

Neil Fleshner, MD, MPH, FRCSC
Professor of Surgery
Martin Barkin Chair of Urology
University of Toronto
Head, Division of Urology
University Health Network
Love Chair in Prostate Cancer Prevention
Princess Margaret Hospital

Michael Jewett, MD
Department of Surgical Oncology (Urology)
Princess Margaret Hospital/
University Health Network
Professor, Department of Surgery (Urology)
University of Toronto

Anil Kapoor, MD, FRCSC
Professor of Surgery (Urology),
McMaster University
Chair, Genito-Urinary Oncology Program,
Juravinski Cancer Centre
Director, McMaster Institute of Urology
Surgical Director, SJH Transplant Program

Thomas E. Keane, MB, ChB, FRCSI, FACS
Professor and Chair
Department of Urology
Medical University of South Carolina

Laurence Klotz, MD, CM
Professor of Surgery, University of Toronto
Chairman, WUOF
Chairman, CURC
Associate Editor, Journal of Urology
Division of Urology
Sunnybrook Health Sciences Centre

Andrew Loblaw, MD, MSc, FRCPC
Clinician Scientist
Odette Cancer Centre / Sunnybrook HSC
Professor, Departments of Radiation
Oncology and Institute for Health Care,
Policy, Management and Evaluation
University of Toronto

Sherif Louis, PhD, PMP
Director, Clinical Operations
3D Signatures Inc.

Sabine Mai, PhD
Professor, Departments of Physiology
and Pathophysiology
Biochemistry and Medical Genetics,
Human Anatomy and Cell Science
University of Manitoba.

Arun Menawat, PhD, MBA
Chief Executive Officer
Profound Medical Inc.

Benjamin Ofori, PhD, MRPharmS
Medical Advisor & Sr. Manager, Oncology
Pharmaceuticals Division
Bayer Inc.

David F. Penson, MD, MPH
Hamilton and Howd
Chair in Urologic Oncology
Professor and Chair,
Department of Urologic Surgery
Director, Center for Surgical Quality
and Outcomes Research
Vanderbilt University Medical Center
Nashville, Tennessee

Peter A. Pinto, MD
Head, Prostate Cancer Section
Director, Fellowship Program
Urologic Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Jehonathan H. Pinthus, MD, PhD
Associate Professor
Department of Surgery
Division of Urology
Surgical Oncology
Juravinski Cancer Program
Hamilton Health Sciences

Frédéric Pouliot, MD, PhD, FRCSC
Urologue-Oncologue/ Urologist-oncologist
Professeur-Adjoint/ Assistant Professor
Département de Chirurgie,
Division d'urologie/ Dept. of Surgery,
Urology Division
Laboratoire d'Uro-Oncologie Expérimentale et
Centre de Recherche du CHU de Québec
Université Laval

Paul S. Rennie, PhD, FCAHS
Director, Laboratory Research
The Vancouver Prostate Centre
Professor, Dept. of Urologic Sciences
University of British Columbia

Srikala Sridhar MD MSc FRCPC
Medical Oncologist,
Princess Margaret Hospital
Site Lead, GU Medical Oncology Group
Associate Professor
University of Toronto

Nawaid Usmani, MD, FRCPC
Associate Professor
Radiation Oncologist, Cross Cancer Institute
University of Alberta, Edmonton

Alexandre R. Ziotta, MD, PhD, FRCSC
Professor, Department of Surgery (Urology)
University of Toronto
Director, Uro-Oncology, Mount Sinai Hospital
Director, Uro-Oncology Fellowship Program
University of Toronto
Staff, Division of Surgical Oncology
Princess Margaret Cancer Centre
University Health Network

TALENT - THE VOID
Michael Kogon (bass)
John Preiner (rhythm guitar)
Paul Johnston (vocal)
Laurence Klotz (keyboard)
Rob Hamilton (drums)
Darrel Drachenberg (lead guitar)

CUIRC NATIONAL HEADQUARTERS CUOG

C2R Conference 2017

Imaging and molecular medicine in urologic oncology | April 21-23 | Toronto